-+ 0.00%
-+ 0.00%
-+ 0.00%

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

The Motley Fool·11/17/2026 03:20:49
Listen to the news

The Australian share market is significantly lower on Tuesday following a weak session on Wall Street overnight.

The benchmark S&P/ASX 200 Index (ASX: XJO) is down 1.4% to 8,922.2 points.

ASX 200 healthcare shares are also down, but not as much as the broader market.

The S&P/ASX 200 Health Care Index (ASX: XHJ) is down 1.2%, at the time of writing.

If we zoom out a bit, healthcare as a market sector is in the midst of an impressive rebound.

The healthcare index hit a 9-year low on 3 June following a prolonged slump driven by many industry challenges.

The index lost 39% of its value over the 12 months leading up to that point.

Among the headwinds were currency changes impacting major ASX 200 enterprises that report in US dollars.

On top of that, interest rate rises and cost of living pressures prompted people to put off non-urgent healthcare.

Add to that higher shipping costs due to the US-Iran conflict, persistently high inflation, rising wage costs, and US regulatory concerns.

But in all slumps comes a pivot point when value investors recognise an opportunity that is too good to ignore.

That occurred for healthcare in June.

Since then, the healthcare index has rocketed 57% higher over just five months.

Many ASX 200 healthcare shares have outperformed amid this new momentum.

Investors appear to have favoured the larger companies in the sector.

Case in point: The share price of sector leader CSL Ltd (ASX: CSL) has more than doubled since 3 June.

In light of this, some experts are encouraging investors to take profits on some shares now.

They're also highlighting some to buy because they believe they have more room to run.

Here are two fresh buy and sell recommendations this week, as showcased on The Bull.

Resmed CDI (ASX: RMD)

The Resmed share price is $35.55, up 1% today and up 38% since the sector pivoted on 3 June.

Steven Springford from Catapult Wealth has a buy call on this ASX 200 healthcare share.

He explained:

Lingering investor concerns about the impact of GLP-1 weight loss drugs on the ResMed business appear to have eased.

The company is also poised to benefit from an under-penetrated global market as many sleep apnoea sufferers remain undiagnosed.

Springford also noted Resmed's 6% revenue growth to $1.415 billion in 1Q FY27.

Earnings are growing faster than sales, which is a sign of efficiency gains.

The shares offer potential upside from here considering they were priced at $39.03 on January 16.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price is $201.94, up 0.1% on Tuesday and up 27% since 3 June.

Pro Medicus shares began recovering long before the sector turned around in June.

The Pro Medicus share price reached a 52-week low of $107.75 in February and then rebounded strongly.

Since that point, the stock is up by more than 75%.

That's partly why Tony Locantro from Alto Capital has a sell rating on this ASX 200 healthcare share.

He said:

The shares have soared since late February…

In our view, the price assumes years of rapid growth and sustained margins.

The recent contract wins show demand for its imaging software. However, the price is exposed to a correction if contract wins slow, or hospital rollouts are delayed.

At this valuation, it's time to consider locking in some gains, in our view.

The post ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts appeared first on The Motley Fool Australia.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026